RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  2. Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
  3. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
  4. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  5. Study siteWest China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06111274, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.

    Inclusion criterion 2

  3. Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).

    Exclusion criterion 2

    Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.

    Exclusion criterion 7

    During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.

    Exclusion criterion 8

  4. ECOG physical strength score 0-2

    Inclusion criterion 5

  5. Measurable disease as defined by RECIST 1.1.

    Inclusion criterion 3

  6. With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.

    Exclusion criterion 3

    With a history of other malignancies within 5 years.

    Exclusion criterion 4

  7. Pregnant or lactating women.

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06111274, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.
  • Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.
  • Measurable disease as defined by RECIST 1.1.
  • Without systemic treatment for pancreatic cancer.
  • ECOG physical strength score 0-2
  • Estimated survival time >=3 months.
  • The adequate bone marrow fuction and coagulation function

Exclusion Criteria:

  • Known allergy or hypersensitivity to any components of the investigational drug product.
  • Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
  • With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
  • With a history of other malignancies within 5 years.
  • During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
  • With conditions that significantly affected the absorption of oral drug.
  • Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
  • During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.
  • Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.
  • Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).
  • Diagnosed with immune deficiency or interstitial lung disease.
  • The patients were vaccinated within 4 weeks before the first treatment.
  • Participated in any drug clinical trial within 4 weeks before the first treatment.
  • Active central nervous system (CNS) metastases.
  • Impaired cardiac function or clinically significant cardiac disease.
  • Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
  • Known active infections from certain viruses, bacteria or parasites.
  • Patients with refractory/uncontrolled ascites or pleural effusion.
  • Pregnant or lactating women.
  • Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.

Quoted from ClinicalTrials.gov, NCT06111274, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06111274, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06111274